background
human
cytomegaloviru
hcmv
preval
congenit
viral
infect
unit
state
europ
caus
signific
morbid
mortal
mother
child
hcmv
also
opportunist
pathogen
immunocompromis
individu
includ
human
immunodefici
viru
hiv
infect
patient
aid
solid
organ
allogen
stem
cell
transplant
recipi
current
treatment
hcmvassoci
diseas
insuffici
due
emerg
druginduc
resist
cytotox
necessit
novel
approach
limit
hcmv
infect
aim
studi
develop
therapeut
peptid
target
glycoprotein
b
gb
major
glycoprotein
hcmv
highli
conserv
across
herpesvirida
famili
specif
inhibit
fusion
viral
envelop
host
cell
membran
prevent
hcmv
entri
infect
result
use
wimleywhit
interfaci
hydrophob
scale
wwih
sever
region
within
gb
identifi
display
high
potenti
interact
lipid
bilay
cell
membran
hydrophob
surfac
within
protein
abil
synthet
peptid
analog
wwihsposit
sequenc
hcmv
gb
inhibit
viral
infect
evalu
human
foreskin
fibroblast
hff
infect
townegfp
strain
hcmv
moi
preincub
peptid
rang
concentr
nm
gfpposit
cell
visual
hour
postinfect
fluoresc
microscopi
analyz
quantit
flow
cytometri
peptid
inhibit
hcmv
infect
demonstr
differ
inhibitori
concentr
curv
indic
peptid
possess
distinct
biophys
properti
peptid
show
inhibit
viral
infect
concentr
inhibit
concentr
respect
peptid
inhibit
infect
concentr
respect
concentr
peptid
individu
fail
inhibit
viral
infect
combin
show
inhibit
hcmv
infect
concentr
conclus
peptid
design
target
put
fusogen
domain
gb
provid
basi
develop
novel
therapeut
prevent
hcmv
infect
human
cytomegaloviru
hcmv
ubiquit
opportunist
pathogen
belong
betaherpesvirida
virul
pathogen
directli
link
immun
statu
host
primari
hcmv
infect
gener
asymptomat
immunocompet
individu
although
caus
mononucleosislik
syndrom
primari
hcmv
infect
viru
establish
lifelong
latenc
period
reactiv
notabl
patholog
consequ
contrast
hcmv
infect
immunocompromis
patient
aid
patient
solid
organ
allogen
stem
cell
transplant
recipi
caus
seriou
diseas
primari
infect
women
right
pregnanc
hcmv
common
caus
congenit
viral
infect
lead
signific
morbid
mortal
congenit
hcmv
infect
also
associ
spontan
abort
prematur
deliveri
intrauterin
growth
restrict
iugr
preeclampsia
risk
primari
infect
seroneg
mother
carri
risk
congenit
infect
major
congenit
infect
babi
asymptomat
birth
howev
subsequ
develop
hear
defect
neurodevelopment
sequela
although
seriou
clinic
sequela
seen
case
mother
acquir
primari
infect
pregnanc
downstream
side
effect
also
seen
case
latent
hcmv
reactiv
mother
reinfect
differ
strain
viru
hcmv
doublestrand
dna
genom
kb
encod
approxim
gene
broad
cellular
tropism
result
potenti
infect
nearli
everi
organ
system
abil
hcmv
enter
wide
rang
cell
type
involv
complex
interact
sever
viral
envelop
glycoprotein
host
cell
surfac
receptor
although
entri
herpesvirus
host
cell
still
poorli
understood
hcmv
virion
envelop
contain
least
virusencod
glycoprotein
involv
cell
attach
penetr
glycoprotein
b
gb
abund
glycoprotein
highli
conserv
among
herpesvirida
glycoprotein
b
play
critic
role
hcmv
entri
process
initi
gb
along
gmgn
involv
tether
virion
heparan
sulfat
proteoglycan
hspg
surfac
host
cell
short
interact
hcmv
hspg
follow
stabl
interact
one
viral
cellular
receptor
name
epiderm
growth
factor
receptor
egfr
plateletderiv
growth
factor
receptor
pdgfr
tolllik
receptor
glycoprotein
b
also
interact
integrin
coreceptor
enhanc
hcmv
entri
integrin
known
synergis
egfr
well
receptor
activ
signal
transduct
pathway
complet
entri
process
viral
cellular
membran
fuse
allow
releas
virionassoci
tegument
capsid
protein
cytoplasm
final
step
viral
entri
host
cell
requir
gb
ghgl
complex
antibodi
hcmv
gb
shown
block
penetr
virion
cell
also
limit
celltocel
infect
impli
gb
play
role
virion
penetr
cell
celltocel
transmiss
well
fusion
infect
cell
recent
isaacson
cowork
use
genet
complement
confirm
gb
requir
fusion
viral
cellular
membran
viru
entri
celltocel
spread
hcmv
import
gb
viral
infect
suggest
viral
envelop
protein
may
ration
target
novel
drug
design
hcmv
infect
highli
preval
popul
due
abil
viru
effici
transmit
host
harbour
period
shed
viru
hcmv
transmit
direct
exposur
infect
bodili
secret
includ
saliva
urin
breast
milk
follow
infect
hcmv
enter
bloodstream
spread
variou
organ
includ
kidney
liver
spleen
heart
brain
retina
esophagu
inner
ear
lung
colon
salivari
gland
abil
hcmv
infect
wide
varieti
cell
type
due
presenc
high
plasma
level
extracellular
viru
primarili
due
celltocel
transmiss
mononuclear
phagocyt
possibl
macrophag
dendrit
cell
precursor
uninfect
tissu
lack
success
hcmv
vaccin
well
toxic
druginduc
resist
associ
current
therapeut
hcmv
indic
viru
continu
pose
signific
public
health
problem
current
treatment
hcmv
diseas
target
viral
replic
fail
due
emerg
drugresist
viru
variant
induct
advers
effect
henc
new
approach
drug
design
hcmv
requir
sinc
hcmv
herpesvirus
establish
lifelong
latenc
human
antivir
therapi
inhibit
viral
entri
may
serv
altern
alreadi
exist
inadequ
therapeut
agent
report
design
develop
character
peptid
specif
inhibit
viral
infect
andor
entri
novel
approach
prevent
hcmv
infect
structur
studi
place
herp
simplex
viru
type
epsteinbarr
viru
gb
class
iii
viral
fusion
protein
vfp
also
includ
vsv
g
member
superfamili
baculoviru
thogotoviru
tent
bornaviru
g
gb
highli
conserv
envelop
protein
amongst
mammalian
avian
herpesviru
gb
hcmv
like
class
iii
vfp
share
structur
featur
gb
member
herpesvirida
class
iii
viral
fusion
protein
share
certain
characterist
found
class
class
ii
viral
fusion
protein
class
iii
viral
fusion
protein
contain
extend
trimer
postfus
form
protein
welldocu
postfus
form
class
viral
fusion
protein
orthomyxovirus
retrovirus
paramyxovirus
arenavirus
coronavirus
similarli
class
ii
viral
fusion
protein
flavivirus
alphavirus
contain
fusion
domain
compris
princip
fusion
loop
class
iii
viral
fusion
protein
also
possess
fusion
domain
well
sever
featur
class
ii
viral
fusion
protein
suggest
two
class
protein
may
share
common
progenitor
class
iii
domain
nomenclatur
use
appli
class
ii
class
iii
viral
fusion
protein
domain
green
domain
ii
yellow
domain
iii
blue
domain
iv
stem
domain
indigo
figur
unifi
nomenclatur
assign
domain
ii
appel
follow
vsv
g
domain
iv
nomenclatur
roch
et
al
baculoviru
domain
nomenclatur
heldwein
et
al
kadlec
et
al
class
iii
fusion
domain
structur
similar
class
ii
viral
fusion
protein
addit
minor
adjust
end
domain
current
class
iii
viral
fusion
protein
number
also
combin
two
interact
domain
domain
iii
ii
roch
vsv
g
nomenclatur
iii
iv
heldwein
nomenclatur
kadlec
baculoviru
nomenclatur
wimleywhit
interfaci
hydrophob
scale
wwih
experiment
determin
hydrophob
scale
provid
quantit
descript
protein
partit
fold
membran
interfac
wwih
scoreposit
sequenc
may
also
interact
hydrophob
surfac
within
protein
often
sequest
within
prefus
form
viral
fusion
protein
addit
similar
overal
structur
postfus
form
class
iii
vfp
addit
similar
distribut
wwihsposit
sequenc
figur
red
similar
includ
least
one
extend
fusion
loop
fusion
domain
domain
ii
one
wwih
scoreposit
sequenc
domain
iii
except
acnpv
protein
contain
anoth
wwih
posit
domain
ii
sequenc
near
hing
region
adjac
domain
herpesviru
gb
protein
addit
wwih
scale
scoreposit
sequenc
domain
case
class
ii
iii
viral
fusion
protein
fusion
loop
fusion
domain
often
contain
sequenc
posit
wwih
score
previou
studi
suggest
synthet
peptid
correspond
overlap
sequenc
viral
fusion
protein
posit
wwih
score
sometim
serv
viral
entri
inhibitor
exampl
enfurvitid
fuzeon
acid
peptid
overlap
wwih
scoreposit
sequenc
transmembran
protein
tm
prevent
viral
fusion
entri
viru
identifi
region
hcmv
gb
high
propens
interact
lipid
bilay
cell
membran
potenti
may
serv
hcmv
entri
inhibitor
employ
membran
protein
explor
version
http
blancobiomoluciedumpex
comput
program
base
wwih
nine
sequenc
signific
posit
wwih
score
identifi
figur
expect
sever
wwih
sequenc
correspond
predict
fusion
domain
hcmv
gb
includ
predict
fusion
loop
one
wwih
scoreposit
sequenc
span
amino
acid
peptid
score
kcalmol
sequenc
split
two
smaller
peptid
second
larg
figur
wimleywhit
interfaci
hydrophob
scale
scoreposit
sequenc
class
ii
iii
viral
fusion
protein
sequenc
repres
class
ii
viral
fusion
protein
dengu
viru
e
class
iii
viral
fusion
protein
high
potenti
interfac
lipid
membran
red
identifi
use
membran
protein
explor
softwar
mpex
version
discuss
text
class
iii
domain
nomenclatur
use
appli
class
ii
iii
viral
fusion
protein
altern
domain
number
scheme
use
roch
et
al
heldwein
et
al
note
parenthes
dengu
viru
denv
e
stem
domain
sequenc
includ
protein
use
determin
crystal
structur
ad
denv
stem
posit
wwih
scale
score
correspond
previous
determin
inhibitor
denv
west
nile
viru
segment
within
fusion
domain
hcmb
gb
score
split
consequ
smaller
peptid
addit
peptid
correspond
anoth
fusion
domain
sequenc
also
synthes
along
addit
peptid
correspond
wwihsposit
domain
hcmv
gb
prevent
dimer
format
cystein
replac
alanin
nine
synthet
peptid
correspond
sequenc
signific
wwih
score
synthes
examin
abil
inhibit
hcmv
infect
hff
cell
peptid
effect
present
tabl
synthet
peptid
test
follow
concentr
wwih
comput
approach
base
upon
experiment
determin
algorithm
estim
propens
amino
acid
sequenc
interact
lipid
membran
interfac
use
method
identifi
sever
region
hcmv
gb
high
interfaci
hydrophob
peptid
analog
sever
region
inhibit
hcmv
infect
low
concentr
figur
test
combin
certain
combin
peptid
peptid
display
increas
inhibit
infect
concentr
nm
figur
result
suggest
hcmv
inhibitori
peptid
identifi
may
serv
figur
determin
region
within
gb
display
high
propens
interact
lipid
surfac
cell
membran
use
wimleywhit
interfaci
hydrophob
scale
wwih
wwih
identifi
segment
protein
prefer
transbilay
helix
conform
unfold
interfaci
locat
use
interfac
scale
membran
protein
explor
mpex
version
comput
program
identifi
particular
segment
hcmv
gb
interfac
scale
measur
residu
free
energi
transfer
within
unfold
polypeptid
chain
water
phosphocholin
bilay
identifi
nine
segment
hcmv
gb
display
high
propens
interact
lipid
surfac
cell
membran
design
peptid
rang
amino
acid
length
analog
identifi
region
gb
basi
potenti
antivir
therapi
success
inhibit
fusion
greatli
depend
biophys
properti
synthes
peptid
concentr
also
size
shape
bind
pocket
hcmv
gb
possibl
potenc
peptid
either
alon
combin
increas
modifi
sequenc
peptid
conjug
peptid
molecul
akkarawongsa
cowork
prepar
librari
overlap
peptid
homolog
ectodomain
herp
simplex
viru
type
screen
abil
peptid
block
infect
seven
peptid
inhibit
infect
concentr
three
peptid
effect
concentr
studi
peptid
residu
identifi
specif
entri
inhibitor
ec
peptid
residu
block
viral
entri
ec
protect
cell
infect
ec
inactiv
virion
solut
ec
seven
inhibitori
peptid
identifi
akkarawongsa
et
al
studi
three
correspond
residu
region
posit
wwih
score
success
studi
affirm
strategi
target
wwih
scoreposit
sequenc
inhibitor
hcmv
two
overlap
peptid
span
residu
wwih
scoreposit
sequenc
analog
sequenc
hcmv
wwih
scoreposit
addit
comparison
across
viral
famili
could
potenti
identif
entri
inhibitor
instanc
inhibitori
peptid
correspond
domain
iv
also
known
stem
analog
hrobowski
dengu
inhibitori
peptid
class
ii
viral
fusion
protein
figur
potenti
inhibitor
hcmv
infect
domain
ii
inhibitori
peptid
residu
identifi
akkarawongsa
et
al
correspond
region
hcmv
inhibitori
peptid
analog
peptid
figur
possibl
inhibitori
peptid
identifi
could
optim
work
hcmv
vice
versa
fusion
domain
hcmv
gb
may
initi
site
interact
directli
lipid
cell
bilay
hcmv
inhibitori
peptid
could
competit
block
interact
trigger
downstream
fusion
event
conform
chang
gb
prematur
inhibitori
peptid
correspond
domain
like
block
lipid
interact
inhibitori
peptid
may
employ
sever
mechan
action
therefor
analog
domain
iii
could
block
receptor
interact
result
studi
found
effect
sever
hcmv
inhibitori
peptid
follow
linear
dosedepend
inhibit
curv
trend
also
report
previous
describ
peptid
inhibitor
dengu
west
nile
virus
possibl
concentr
one
peptid
high
peptid
may
selfassoci
prevent
interf
viru
infect
addit
screen
synthet
peptid
abil
inhibit
hcmv
infect
alon
test
peptid
combin
possibl
peptid
block
hcmv
entri
distinct
step
fusion
process
two
peptid
work
addit
block
fusion
virion
host
cell
membran
must
uniqu
amino
acid
sequenc
biophys
properti
present
certain
concentr
allow
interact
gb
possibl
glycoprotein
instrument
fusion
event
peptid
test
togeth
show
inhibit
concentr
figur
work
addit
fashion
result
may
due
peptidepeptid
interact
allow
interfer
gb
trimer
format
necessari
conform
chang
virion
requir
success
fusion
occur
sever
drug
includ
ganciclovir
oral
prodrug
valganciclovir
foscarnet
cidofovir
fomivirsen
approv
treatment
hcmvassoci
diseas
drug
except
fomivirsen
common
target
viral
dna
polymeras
list
antihcmv
drug
provok
drugspecif
side
effect
includ
leukopenia
thrombocytopenia
anemia
bone
marrow
hypoplasia
diarrhea
renal
toxic
also
emerg
clinic
relev
drugresist
hcmv
new
drug
efficaci
toxic
treatment
hcmv
infect
urgent
need
inhibitori
peptid
identifi
serv
basi
develop
novel
therapeut
hcmv
antivir
agent
could
use
antivir
treatment
reduc
viral
load
pregnant
women
neonat
clear
hcmv
infect
fetu
pregnanc
studi
demonstr
placent
infect
hcmv
occur
transmiss
viru
fetu
suggest
placenta
play
role
vertic
transmiss
hcmv
mother
fetu
also
placent
viral
infect
implic
spontan
abort
earli
pregnanc
occur
fifteen
percent
women
primari
hcmv
infect
placent
patholog
result
hcmv
infect
pregnanc
may
also
caus
prematur
deliveri
intrauterin
growth
restrict
iugr
preeclampsia
enfurvitid
acid
peptid
also
known
fuzeon
work
inhibit
structur
rearrang
block
fusion
virion
target
cell
membran
brennanbenson
et
al
show
fuzeon
prevent
vertic
transmiss
pregnanc
cross
placenta
shown
peptid
effect
prevent
hcmv
infect
lead
peptid
studi
modifi
increas
efficaci
solubl
deliveri
current
avail
drug
treat
hcmv
infect
approv
treat
pregnant
women
due
potenti
high
toxic
hcmv
infect
neonat
treat
toxic
compound
case
high
morbid
antivir
peptidebas
agent
may
develop
result
studi
would
requir
activ
viral
encod
protein
phosphoryl
cellular
enzym
incorpor
grow
viral
dna
viral
dna
polymeras
current
therapeut
peptid
therapeut
would
predict
provok
druginduc
resist
signific
problem
exist
fdaapprov
therapeut
treat
hcmv
infect
sinc
employ
differ
mechan
action
cell
viabil
assay
demonstr
effect
peptid
statist
signific
toxic
highest
concentr
test
studi
data
shown
consequ
expect
advers
effect
toxic
due
treatment
develop
synthet
peptid
wwih
experiment
determin
algorithm
use
estim
propens
amino
acid
sequenc
interact
lipid
membran
interfac
sequenc
hcmv
gb
posit
wwih
score
identifi
use
membran
protein
explor
mpex
version
http
blancobiomoluciedumpex
comput
program
base
wwih
hcmv
gb
synthet
peptid
synthes
solid
phase
convent
chemistri
genem
synthesi
inc
san
francisco
ca
peptid
purifi
reversephas
high
perform
liquid
chromatographi
confirm
amino
acid
analysi
electrospray
mass
spectrometri
peptid
stock
solut
prepar
dimethyl
sulfoxid
dmso
spectroscopi
grade
vv
h
peptid
concentr
determin
absorb
aromat
side
chain
nm
smartspec
biorad
hercul
ca
town
strain
hcmv
contain
green
fluoresc
protein
gfp
express
cassett
obtain
dr
daniel
streblow
oregon
health
scienc
univers
propag
human
foreskin
fibroblast
hff
viral
supernat
collect
day
cpe
observ
centrifug
clear
cell
debri
filter
filter
hff
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
g
uml
streptomycin
mgml
glutamax
mm
hff
seed
densiti
cell
well
plate
hour
prior
infect
hff
wash
dpb
mockor
virusinfect
minut
rt
townegfp
strain
hcmv
moi
preincub
differ
concentr
inhibitori
peptid
minut
infect
viru
remov
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
g
uml
streptomycin
mgml
glutamax
mm
ad
well
cell
incub
hour
gfpposit
cell
visual
hour
postinfect
fluoresc
microscopi
quantifi
use
flow
cytometri
hff
cell
trypsin
centrifug
resuspend
fb
dpb
gfpposit
cell
quantifi
use
flow
cytometri
cytom
fc
beckman
coulter
fullerton
ca
